ARTICLE | Company News
Amgen, AZ halt brodalumab trials
May 27, 2015 12:46 AM UTC
Amgen Inc. (NASDAQ:AMGN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) will halt clinical studies of investigational psoriasis therapy brodalumab, including a Phase III trial to treat psoriatic arthritis, Amgen spokesperson Trish Hawkins told BioCentury.
Amgen had said Friday it would exit a collaboration with AZ to develop the IL-17 inhibitor due to concerns that the compound will require restrictive labeling based on suicidal ideation and behavior seen in clinical trials. ...